中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
19期
84-85,86
,共3页
廖晓焰%周辉%王涛%何伟%贺娟%孙晓燕
廖曉燄%週輝%王濤%何偉%賀娟%孫曉燕
료효염%주휘%왕도%하위%하연%손효연
盐酸利托君注射液%先兆早产%硫酸镁%临床效果%新生儿
鹽痠利託君註射液%先兆早產%硫痠鎂%臨床效果%新生兒
염산리탁군주사액%선조조산%류산미%림상효과%신생인
ritodrine hydrochloride injection%aura preterm birth%magnesium sulfate%clinical effect%newborn
目的:观察盐酸利托君注射液治疗先兆早产的临床效果及对新生儿的影响。方法选取2013年8月至2014年9月就诊的110例先兆早产患者,根据治疗方法进行分组,对照组给予硫酸镁治疗,试验组给予盐酸利托君注射液治疗。结果试验组患者保胎成功率为96.36%、宫缩显效时间(2.11±0.62)h、延长分娩时间(14.32±10.43)d,显著优于对照组的63.64%、(5.60±1.23)h、(22.13±14.25)d( P﹤0.05)。试验组新生儿死亡率为1.82%、新生儿出生体重(2567.4±229.7)g、新生儿阿氏( Apgar )评分(9.3±0.8)分,显著优于对照组的18.18%、(2140.8±162.3)g、(8.3±0.5)分( P﹤0.05)。试验组患者用药后不良反应发生率为7.27%,明显低于对照组的32.73%( P﹤0.05)。结论先兆早产患者应用盐酸利托君注射液治疗的临床效果显著,可有效抑制孕妇宫缩,延长孕妇的妊娠时间,保胎成功率较高且新生儿情况良好,安全可靠。
目的:觀察鹽痠利託君註射液治療先兆早產的臨床效果及對新生兒的影響。方法選取2013年8月至2014年9月就診的110例先兆早產患者,根據治療方法進行分組,對照組給予硫痠鎂治療,試驗組給予鹽痠利託君註射液治療。結果試驗組患者保胎成功率為96.36%、宮縮顯效時間(2.11±0.62)h、延長分娩時間(14.32±10.43)d,顯著優于對照組的63.64%、(5.60±1.23)h、(22.13±14.25)d( P﹤0.05)。試驗組新生兒死亡率為1.82%、新生兒齣生體重(2567.4±229.7)g、新生兒阿氏( Apgar )評分(9.3±0.8)分,顯著優于對照組的18.18%、(2140.8±162.3)g、(8.3±0.5)分( P﹤0.05)。試驗組患者用藥後不良反應髮生率為7.27%,明顯低于對照組的32.73%( P﹤0.05)。結論先兆早產患者應用鹽痠利託君註射液治療的臨床效果顯著,可有效抑製孕婦宮縮,延長孕婦的妊娠時間,保胎成功率較高且新生兒情況良好,安全可靠。
목적:관찰염산리탁군주사액치료선조조산적림상효과급대신생인적영향。방법선취2013년8월지2014년9월취진적110례선조조산환자,근거치료방법진행분조,대조조급여류산미치료,시험조급여염산리탁군주사액치료。결과시험조환자보태성공솔위96.36%、궁축현효시간(2.11±0.62)h、연장분면시간(14.32±10.43)d,현저우우대조조적63.64%、(5.60±1.23)h、(22.13±14.25)d( P﹤0.05)。시험조신생인사망솔위1.82%、신생인출생체중(2567.4±229.7)g、신생인아씨( Apgar )평분(9.3±0.8)분,현저우우대조조적18.18%、(2140.8±162.3)g、(8.3±0.5)분( P﹤0.05)。시험조환자용약후불량반응발생솔위7.27%,명현저우대조조적32.73%( P﹤0.05)。결론선조조산환자응용염산리탁군주사액치료적림상효과현저,가유효억제잉부궁축,연장잉부적임신시간,보태성공솔교고차신생인정황량호,안전가고。
Objective To study Ritodrine Hydrochloride injection treatment effect of Aura preterm birth and influence on newborn. Methods From August 2013 to September 2013 in our hospital 110 patients with aura premature birth, according to the treatment methods, and in the control group patients were given magnesium sulfate, yet in the experimental group patients were given hydrochloride injection treatment. The clinical efficacy of two groups of patients and effect of newborn was compared. Results in the experimental group spuc success rate ( 96. 36% ) , patients with contractions time ( 2. 11 ± 0. 62 ) h, the extend time of delivery ( 14. 32 ± 10. 43 ) d, spuc success rate ( 63. 64% ) , significantly better than the control group contractions time ( 5. 60 ± 1. 23 ) h, the extend time of delivery ( 22. 13 ± 14. 25 ) d, statistical significance difference ( P ﹤ 0. 05 ) . Experimental neonatal mortality ( 1. 82% ) , neonatal birth weight ( 2 567. 4 ± 229. 7 ) g, newborn Apgar score ( 9. 3 ± 0. 8 ) significantly better than control group in neonatal mortality rate ( 18. 18% ) , neonatal birth weight ( 2 140. 8 ± 162. 3 ) g, newborn Apgar score ( 8. 3 ± 0. 5 ) points, statistical significance difference ( P ﹤ 0. 05 ) . In experimental group incidence of drug adverse reactions ( 7. 27% ) after the drug was significantly lower than the control group ( 32. 73% ) , the incidence of adverse reactions, statistical significance difference ( P ﹤ 0. 05 ) . Conclusion The clinical effect of Rito-drine Hydrochloride injection on patients is remarkable, effectively restrain pregnant women contractions, extended the pregnant women of pregnancy, spuc success rate is higher, the condition is good, safe and reliable, and can be popularized in clinical application.